Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02834013
Recruitment Status : Recruiting
First Posted : July 15, 2016
Last Update Posted : August 11, 2022
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 31, 2023
Estimated Study Completion Date : October 31, 2023
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):